At the recommendation of the FDA, the new boosters protect against XBB variants, which made up 95% of all U.S. Covid cases in June.
Trump Claims Mar-A-Lago Worth $1.5 Billion In Latest Plea To Drop Fraud Case—But Judge Ruled It’s Wildly Inflatedon Tuesday to Novavax’s new Covid vaccine designed to target the coronavirus’ dominant XBB sublineage, which is fueling a spike in cases, hospitalizations and deaths across the country.
Deaths increased by 8% between September 17 and September 23, and hospitalizations stood at 19,079 during this period, according to the CDC’s most recent data. EG.5, or the “Eris” variant—part of the XBB lineage—is the dominant strain in the U.S., making up 29.4% of all cases between September 17 and September 30. As of June, the XBB omicron subvariants made up 95% of all Covid cases in the U.S., according to an FDA.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.Health officials see Novavax's protein-based vaccine as a valuable alternative for people who don't want to take messenger RNA shots from Pfizer and Moderna.
Read more »
Novavax Stock Jumps After FDA Approves Updated Covid VaccineShares were up more than 10% on the news, which came more than three weeks after vaccines from Moderna and Pfizer.
Read more »
FDA Authorizes Novavax’s Updated Covid VaccineThe shot has been updated to target a strain of the coronavirus that was circulating earlier this year.
Read more »
US FDA authorizes Novavax's updated COVID shot By ReutersUS FDA authorizes Novavax's updated COVID shot
Read more »
FDA authorizes updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.Health officials see Novavax’s protein-based vaccine as a valuable alternative for people who don’t want to take messenger RNA shots from Pfizer and Moderna.
Read more »
Novavax updated COVID vaccine gets FDA approvalStock jumps 12% on regulatory approval of new shot
Read more »